Table 2.

Univariate probabilities^a of transplant outcomes among patients receiving Fludarabine + Busulfan + Thymoglobulin (Cases) or Busulfan + Cyclophosphamide (Controls).

	CASES FluBuTG		CONTROLS BuCy
Outcome event	N eval	Prob (95% CI)	N eval	Prob (95% CI)	P-value
Grade II–IV AGVHD	120		215
@ 100 days		15 (9–22) %		34 (28–41)%	<0.001++
Chronic GVHD	120		213b
@ 1 year		39 (30–48) %		32 (25–39) %	0.20++
@ 2 years		39 (30–48) %		34 (27–41) %	0.357++
Treatment related mortality	120		215
@ 1 year		9 (5–15) %		24 (18–30) %	<0.001++
@ 3 years		11 (6–17) %		30 (24–37) %	<0.001++
@ 5 years		12 (7–19) %		34 (27–41) %	<0.001++
Relapse/progression	120		215
@ 1 year		29 (21–38) %		12 (8–17) %	<0.001++
@ 3 years		36 (27–45) %		20 (14–25) %	<0.001++
@ 5 years		42 (32–52) %		20 (15–26) %	<0.001++
Overall survival	120		215		0.157+
@ 100 days		91 (85–95) %		82 (76–87) %	0.01++
@ 1 year		76 (68–83) %		66 (60–73) %	0.06++
@ 3 years		65 (56–73) %		55 (48–62) %	0.07++
@ 5 years		58 (49–67) %		51 (43–58) %	0.22++

Abbreviations: CI= confidence interval; GVHD= graft-versus-host disease; BuCy= oral busulfan + cyclophosphamide; FluBuTG= fludarabine + IV busulfan + thymoglobulin; CY=Cyclophosphamide; AGVHD =acute graft-versus-host-disease.

^aProbabilities of overall survival were calculated using the Kaplan-Meier product limit estimate. Probabilities of relapse, treatment-related mortality, acute GVHD and chronic GVHD were calculated using the cumulative incidence estimate.

^bThere are 2 patients missing CGVHD outcome data. These patients are missing the date of CGVHD onset.

⁺Log-rank test p-value.

⁺⁺Pointwise p-value